Status: Bibliographieeintrag
Standort: ---
Exemplare:
---
| |  Online-Ressource |
|---|
| Verfasst von: | Stock, Sophia [VerfasserIn]  |
|---|
| | Schmitt, Michael [VerfasserIn] |
|---|
| | Sellner, Leopold [VerfasserIn] |
|---|
| Titel: | Optimizing manufacturing protocols of chimeric antigen receptor T cells for improved anticancer immunotherapy |
|---|
| Verf.angabe: | Sophia Stock, Michael Schmitt and Leopold Sellner |
|---|
| E-Jahr: | 2019 |
|---|
| Jahr: | 10 December 2019 |
|---|
| Umfang: | 21 S. |
|---|
| Teil: | volume:20 |
|---|
| | year:2019 |
|---|
| | number:24 |
|---|
| | extent:21 |
|---|
| Fussnoten: | Gesehen am 17.02.2020 |
|---|
| Titel Quelle: | Enthalten in: International journal of molecular sciences |
|---|
| Ort Quelle: | Basel : Molecular Diversity Preservation International, 2000 |
|---|
| Jahr Quelle: | 2019 |
|---|
| Band/Heft Quelle: | 20(2019,24) Artikel-Nummer 6223, 21 Seiten |
|---|
| ISSN Quelle: | 1422-0067 |
|---|
| | 1661-6596 |
|---|
| Abstract: | Chimeric antigen receptor (CAR) T cell therapy can achieve outstanding response rates in heavily pretreated patients with hematological malignancies. However, relapses occur and they limit the efficacy of this promising treatment approach. The cellular composition and immunophenotype of the administered CART cells play a crucial role for therapeutic success. Less differentiated CART cells are associated with improved expansion, long-term in vivo persistence, and prolonged anti-tumor control. Furthermore, the ratio between CD4+ and CD8+ T cells has an effect on the anti-tumor activity of CART cells. The composition of the final cell product is not only influenced by the CART cell construct, but also by the culturing conditions during ex vivo T cell expansion. This includes different T cell activation strategies, cytokine supplementation, and specific pathway inhibition for the differentiation blockade. The optimal production process is not yet defined. In this review, we will discuss the use of different CART cell production strategies and the molecular background for the generation of improved CART cells in detail. |
|---|
| DOI: | doi:10.3390/ijms20246223 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.3390/ijms20246223 |
|---|
| | Verlag: https://www.mdpi.com/1422-0067/20/24/6223 |
|---|
| | DOI: https://doi.org/10.3390/ijms20246223 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | adoptive cell therapy |
|---|
| | CAR |
|---|
| | CART |
|---|
| | CART cell production |
|---|
| | chimeric antigen receptor |
|---|
| | cytokines |
|---|
| | immunotherapy |
|---|
| | T cell activation |
|---|
| | T lymphocyte |
|---|
| K10plus-PPN: | 1690159073 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Optimizing manufacturing protocols of chimeric antigen receptor T cells for improved anticancer immunotherapy / Stock, Sophia [VerfasserIn]; 10 December 2019 (Online-Ressource)
68489628
